NCT00609167 · OUTCOME

Participants Who Successfully Completed Collection of Peripheral Blood Stem Cells for Transplant

Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma · Source last updated 2011-05-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: participants
Interval / dispersion: Not reported
Time frame: After 4 cycles of treatment

What was measured

Evaluation of the ability to successfully collect peripheral blood stem cells following four months (cycles) of combination therapy.

Analysis population: At the time of publication, data was available on 18 patients for group 2.

Groups in this outcome

CyBorD (Bortezomib 1.3mg/m^2)

Bortezomib 1.3mg/m\^2 by IV days 1, 4, 8 \& 11 Cyclophosphamide 300mg/m\^2 PO days 1, 8, 15 \& 22 Dexamethasone 40mg PO days 1-4, 9-12, 17-20

CyBorD (Bortezomib 1.5mg/m^2)

Bortezomib 1.5mg/m\^2 by IV days 1, 8, 15 \& 22 Cyclophosphamide 300mg/m\^2 PO days 1, 8, 15 \& 22 Dexamethasone 40mg PO cycle 1-2 days 1-4, 9-12, 17-20, cycle 3 and beyond days 1, 8, 15 \& 22

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
CyBorD (Bortezomib 1.3mg/m^2)	33
CyBorD (Bortezomib 1.5mg/m^2)	18

Reported measurements

Source class 1

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
CyBorD (Bortezomib 1.3mg/m^2)	33	Not reported	Not reported	Not reported	Not reported
CyBorD (Bortezomib 1.5mg/m^2)	17	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
33
group Id
OG001
value
17

denoms

counts
group Id
OG000
value
33
group Id
OG001
value
18
units
Participants

description

Evaluation of the ability to successfully collect peripheral blood stem cells following four months (cycles) of combination therapy.

groups

description
Bortezomib 1.3mg/m\^2 by IV days 1, 4, 8 \& 11 Cyclophosphamide 300mg/m\^2 PO days 1, 8, 15 \& 22 Dexamethasone 40mg PO days 1-4, 9-12, 17-20
id
OG000
title
CyBorD (Bortezomib 1.3mg/m^2)
description
Bortezomib 1.5mg/m\^2 by IV days 1, 8, 15 \& 22 Cyclophosphamide 300mg/m\^2 PO days 1, 8, 15 \& 22 Dexamethasone 40mg PO cycle 1-2 days 1-4, 9-12, 17-20, cycle 3 and beyond days 1, 8, 15 \& 22
id
OG001
title
CyBorD (Bortezomib 1.5mg/m^2)

param Type

NUMBER

population Description

At the time of publication, data was available on 18 patients for group 2.

reporting Status

POSTED

time Frame

After 4 cycles of treatment

title

Participants Who Successfully Completed Collection of Peripheral Blood Stem Cells for Transplant

type

SECONDARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice